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Pharmacodynamics and pharmacokinetics
in the elderly
Aging is not disease and is not treatable by medicaments.
Many older people admitted to hospital or reviewed during
long term hospitalization improved greatly, when the drug
regimen that they had been taking, was stopped.
(WHO)
Abstract
The paper deals with changes in pharmacodynamics (the study of what the
drug does to the body) and pharmacokinetics (the study of what the body does
to the drug) in the elderly. Elderly population takes 25–30 per cent of drugs
taken by total population. In the elderly pharmacodynamics and pharma-
cokinetics are altered. According to pharmacokinetics, gastric juice pH is
elevated which influences drug solubility and absorption. Drug distribution is
decreased in the elderly because of decreased cardiac output, increased peri-
pheral vascular resistance, diminished blood flow in the liver and the kidneys,
reduced total amount of water in the body. Drug metabolism and biotrans-
formation mainly take place in the liver and is reduced very often. Drug
elimination is reduced very often because of reduced renal reserve: creatinine
clearance is reduced in the elderly in spite of the fact that the serum values
remaining in the normal range. Pharmacodynamics could be altered in the
elderly, as a consequences of receptor binding, of postreceptor effects, and of
chemical interactions. The clinical effects of drug concentrations could be
greater or smaller than those in middle-aged or younger persons.
INTRODUCTION
Elderly population takes 25–30 per cent of drugs taken by totalpopulation. In the elderly pharmacodynamics and pharmacokine-
tics are altered. Pharmacodynamics is the study of what the drug does to
the body, and pharmacokinetics is the study of what the body does to the
drug (1–11).
Gastric juice pH is elevated which influences drug solubility and
absorption. Athophic gastritis occurs, absorption surface diminishes,
gastric contents are more slowly discharged, intestinal motility de-
creases, intestinal diverticulosis is present. Drugs absorbed by passive
diffusion are freely resorbed (e.g. indomethacin) whereas the absorp-
tion of drugs that are actively transported is slower. Passive diffusion is
quicker if the drug is soluble in the lipids. There are two important
factors of drug absorption from the gastrointestinal tract: constant
absorption rate and bioavailability of the drug. Absorption from the
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Overview
bowel depends also on the drug conversion by the bac-
teria present in the gastrointestinal tract.
Drug distribution is decreased in the elderly. Reasons
for this are numerous: decreased cardiac output, increas-
ed peripheral vascular resistance, diminished blood flow
in the liver and the kidneys, reduced total amount of
water in the body. The serum albumin concentration is
also reduced during aging, by 30 per cent in comparison
to younger age. This is important because many drugs
are linked on plasma albumins and lower concentration
of serum albumins means higher pharmacological acti-
vity of the drug. The volume of distribution e.g. the drug
concentration in the body divided by its concentration in
the blood, is lowered by the old age. Hydrophylic drugs
have a decreased volume of distribution, and lipophylic
ones an increased volume of distribution (1, 5–11).
Drug metabolism and biotransformation mainly take
place in the liver. This process is reduced very often in the
elderly. Besides the liver, this process takes place in the
lungs, in the plasma, in the gastrointestinal tract muco-
sis, and in the kidneys. The microsomal liver activity is
reduced. Here the drug is changed into a less active or
inactive substance, rarely into a more active one. The
processes of the phase 1. of drug metabolism in the liver
(hydroxylation, N-dealkylation, N-demethylation, sul-
foxydation, nitroreduction and hydrolysis) are diminish-
ed. It seems that the processes of the phase 2. (conjuga-
tion) does not change with the old age. Examples of the
drugs of the 1.phase are: propranolol, benzodiazepines
etc. Drug clearance by the liver with digoxin, diazepam
can be reduced, average with quinidine, prazosine, or
increased with verapamil, nifedipine, doxepine. Drug
elimination half-life becomes longer with the old age
(1,5,12–16).
Drug elimination takes place mainly in the kidneys: by
glomerular filtration, tubular excretion or by both ways.
Due to reduced renal reserve, creatinine clearance is
reduced during in the elderly in spite of the fact that the
serum values remaining in the normal range. Many drugs
are weak acids or weak bases. They can be soluble in
water, lipids, in tubular fluid-like ions or undissociated
acid soluble in lipids. Tubular cells behave as a lipid
membrane. Therefore the undissociated drug molecules
will diffuse back faster. The back diffusion of the drug
depends on the urine pH. In alkaline urine the elimina-
tion of some drugs is reduced and their action is longer,
for example amphetamine. Some drugs reduce renal
blood flow, for instance propranolol, and should there-
fore be avoided in elderly person with reduced creatinine
clearance. Tubular function also decline with age, so that
biological half-life of penicilline in the elderly is two
times longer than in younger, the same being valid for
cephalosporins, probenecid etc. (1, 5, 8, 10, 11).
In the elderly non-fat body mass is reduced, as well as
the total amount of body water, which reduces the drug
distribution volume of hydrosoluble drugs. A relative
increase of body fats is present. Plasma albumin con-
centration is decreased, which causes the alteration of
volume of distribution. Heart reserve is decreased, which
increases the danger of congestive heart failure in case of
the use of fluid retaining drugs or of those that have
negative inotropic action. Metabolizing capacity of the
liver, lungs vital capacity and renal reserve are reduced.
Because of that, some drugs that are cleared by those
organs have to be used in reduced doses in avoid of
accumulation and possible side effects.
Pharmacodynamics could be altered in the elderly, as
a consequences of receptor binding, of postreceptor ef-
fects, and of chemical interactions. The clinical effects of
drug concentrations could be greater or smaller than
those in middle-aged or younger persons.
DRUG INTERACTIONS
Many drugs that bind to plasma albumins are res-
ponsible for the occurrence of drug interactions when
they free themselves from the albumin-drug complex.
Drug interactions are more frequent in the elderly as
microsomal hepatic enzymes are inhibited because of
polypharmacy (polypragmasia). Polypharmacy is the use
of multiple drugs. The interactions of antihypertensives
and general anesthetics are well known, which may lead
to arterial hypotension. Another cause for drug inter-
actions, apart from polypharmacy, is a modified drug
effect also. The greater number of drugs an elderly pa-
tient takes, the great danger of interaction occurs. If two
drugs are taken simultaneously by an elderly person,
prospect for an interaction occurrence are almost 6 per
cent. If 5 drugs are taken, these chances amount up to 50
per cent, and if 8 or more drugs are taken, prospects for
an interaction are near 100 per cent. It should be there-
fore striven to limit the number of drugs taken by an
elderly patient to no more than three: the lowest number
of used drugs should be striven at. Drug interactions
should occur at any level, from absorption to elimination.
Well-known is the competition on the receptor when
several drugs are applied simultaneously. This is often
used for therapeutic purpose, like the use of naloxone in
opiate intoxication, since it has a great affinity for opiate
receptors (8, 11).
ADVERSE DRUG REACTIONS
Adverse drug reactions occur about twice as often in
the elderly, who are more sensitive to drugs than the
younger. The use of morphine as an analgetic, in the
elderly could be an example for this. In the elderly a
lower doses than in the younger must be applied because
the usual dose provokes the central nervous system de-
pression. ß adrenergic receptors are less sensitive to ago-
nists than to antagonists. The bioavailability of drugs
with the first pass hepatic metabolism can be both in-
creased and decreased. Baroreceptor function is often
altered in the old age which is directly connected with the
use of antihypertensives. Adverse drug reactions are more
frequent in an elderly patient, because of careless clinical
estimation of his clinical condition, which can result in
inadequate chosen drug, or because of overdosing of the
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drug caused by numerous reasons. Another cause of
adverse drug reactions is insufficient control of the effect
of the drugs used for a longer period of time, e.g. digitalis
glycosides (10, 11, 14, 16).
POLYPHARMACY
Polypharmacy is often a problem in the elderly, who
usually take 4 to 5 different drugs daily. These patients
generally suffer from several diseases simultaneously, with
many new disease elements. This imposes adequate and
careful dosing. Yet, even when the diagnosis has been
adequately established, elderly patients are inadequately
managed. Reasons for this are numerous: disrespect for
particular alterations in the body of an elderly person, too
high dose applied, inadequate treatment of each disease
symptoms and disrespect for specific changes in drug
effect on the body of an elderly patient. The unjustifiable
number of drugs taken by an elderly patient is, according
to the data, from 3–12 daily, the significant number being
ineffective. An elderly patient who visit many physicians
is in danger for polypharmacy. Apart from his general
practitioner, rather often a patient consults different spe-
cialists, and if the old patient is not approached com-
prehensively, the number of prescribed drugs will be
rather large. Adverse drug reactions are proportional in
number to the number of drugs taken. The patient often
does take all these drugs. If he makes a selection and
takes only some of the many drugs prescribed, he may not
harm himself if he drops (by chance) drugs of uncertain
efficacy or certain uneffectiveness. On the contrary, he will
harm himself, if he stops taking essential drugs, i.e. digita-
lis glycosides, antihypertensives, calcium-channel block-
ing agents, anticoagulants etc. (1, 5, 7, 8, 10, 11, 14, 16).
THE PRINCIPLES OF DRUG TRIALS
IN THE ELDERLY
In avoid polypharmacy i.e. the use of multiple medi-
cations, it is necessary to make the basis guidelines of the
clinical pharmacology of the old age using a scientific
approach to drug trials and individualized therapy. Poly-
pharmacy in the elderly has to be reduced by eliminating
useless drugs, uneffective drugs, unnecessary drugs, un-
effective drugs, drugs with duplicate effects, drugs with
undesirable side effects. In this field a cost-benefit ratio of
health care for elderly patients is important because it is
estimated that 25 per cent of all prescribed drugs taken by
an elderly patient, is probably unnecessary. Many facts
that are often lacking, are necessary when a drug is
prescribed to an old patient. Here it must be taken into
account that 4 out of 5 elderly patients suffer from at least
one of chronic disease The most common diseases in the
elderly for which a new drug is investigated are coronary
heart disease, peripheral vascular disease, senile demen-
tia. Drug therapy is particularly present in the elderly
suffering from arterial hypertension, congestive heart fail-
ure, cardiac arrhythmias, arthrosis, arthritis, pneumonia,
osteoporosis, urinary tract infections including prostatic
diseases. This must be taken into account when the
patients group in which the new drug will be investi-
gated is selected, considering the patients sample and
measuring during the trial (10, 11).
Prior to drug administration in an elderly person, its
pharmacokinetics must be analyzed in younger healthy
volunteers. The results obtained must be analyzed.
In the elderly not to forget organs and organic systems
changes and reduction of ability to excrete drugs: the
reduction of renal reserve. It is desirable that the drug is
investigated in two groups of patients: one consisting of
younger patients aged 21-39 and the other one of elderly
patients of chronological ages 65 or more. Elderly of
course does not exclude an examinee from the trial. It
must be said that the majority of clinical drug trials in
elderly persons conducted nowadays have included pa-
tients up to 75 years of age; must often the age was even
below 70. Of course, examinees should be included in
clinical trials, particularly those over 75. This is the way
to collect precise informations on drug use in patients
over 75.
There are age variances regarding pharmacodyna-
mics (the relation between the clinical effect and the
plasma drug level) and pharmacokinetics (movements of
drugs from absorption, distribution, binding to plasma
albumins, metabolism, and elimination). Concerning the
elderly in whom a drug is investigated, the trial should be
performed on a small number of patients. Simultaneous-
ly the investigation should be performed on the young
and the two groups should be compared in order to
estimate the difference between the groups. A certain
number of elderly patients can be included in phase 2.
and 3., although most frequently they take part in phase
3. of therapeutic clinical trial only. It is significant that the
drug effect on the body can be observed after only a few
doses. Here the dose-dependent effect will be determin-
ed. When the drug is investigated simultaneously in the
younger and in the elderly, plasma drug level must be
analyzed in both groups, in order to determine the dif-
ferences between the age groups. This trial must be com-
parative (10,11). The following points must be taken into
consideration while clinically investigating drugs in the
elderly:
1. The aim of the trial in equal to the one in other age
groups. Therapeutic efficacy and relative safety of the
new drug in comparison with the pre-existing one must
be proved. The patients in whom the new drug is indi-
cated must be particularly selected, optimal dose and
side-effects should be found;
2. Types of trial: a double-blind randomized trial is
ideal, but it can also be controlled, comparative, open
and blind. Most often, phase 3. is performed;
3. The selection of patients is a certain problem, as
these patients suffer from several simultaneous diseases.
Quite often the trial will be started in the hospital and
later the drug will be administered in out-patient units.
All other pharmacotherapy must be maximally reduced;
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4. Measurements: individualized pharmacotherapy
should be striven at. Measurements must result from a
precise trial protocol, it must be simple and non-invasive
whenever it is possible; the determination of drug con-
centration in the plasma should be insisted upon.
GENERAL PRINCIPLES OF DRUG
THERAPY
Chronic diseases are more frequent in the elderly than
in other age groups. Therefore elderly take drugs more
frequent, although very often not in a proper way. Ac-
cording to some data, more than 60 per cent of eldrly
patients take driug inadequately. There are numerous
reasons for that, the basic one being polypragmasia. Above
25 per cent of those (60 per cent) elderly patients make
serious mistakes in drug therapy. The largest number of
administered drugs – the most frequent mistakes are.
When a drug is used in an elderly person, the following
questions have to be answered: Is the treatment ne-
cessary? Is it possible? What are its expected results?
Not all disease symptoms have to be treated. Many
chronic diseases cannot be treated with drugs. The drug
administered to an elderly patient must be the one with
well known adverse effects. It is the fact that in such
patients the regularity of taking the therapy is reversely
proportionate to the number of drugs he is taking must
not to be forgotten. The drug,s purpose must be carefully
stated orally and in writing, and this aspect must be taken
into as much consideration as it should be necessary. In
old patients it should be striven to give a single daily dose
of, for instance digitalis glycosides, diuretics, cortico-
steroids etc. The patients attention must also be drawed
to the connection between the drug and meals: should
the drug be taken before, after or independently from a
meal? It is especially important to warn the patient about
whether a drug can be taken simultaneuously with other
drugs, and which drugs can be combined as well as
which drugs cannot be combined (e.g. antacids and di-
gitalis glycosides). If we make the drug taking simpler, it
is more probable that an older patient will take the drug.
Also, if a chronic disease is treated for a long period of
time, the same brand name and the same preparation
should be prescribed since this is usually how patients
recognize the drug: by colour and the preparation (7, 10,
11, 14, 16).
It is important to take care about the drug,s package
and, if a bottle is used, to make sure that the patient can
open it. It is better not to prescribe drops to elderly
patients. They will, their eye-sight being worse and
hands shaking, probably pour a greater number of drops
and risk the adverse drug reactions. Sometimes the old
patient cannot take out his drug from the plastic package
and therefore does not take the drug. Drugs should
always be in the shape of tablets or dragees in bottles with
wide cover that opens by turning.
It would be good to write the time of the drug-taking
and the dose in a calendar for the old patient. The are
plastic boxes in which a dose necessary once to three
times a day for 7 days can be put. This is very handy for
an old person. It must be refilled once a week and at the
same time it presents therapy control: thus it is im-
mediately obvious if the patient has taken the drugs in
appropriate doses. This box had 3 horizontal and 7 ver-
tical walls the name of the day on them.
The patient,s family must be familiar in details with
the therapy, especially when they take care of him. All
drugs but those that the patient must take, should be
removed from where he can reach them in case he makes
a mistake. It would be good too, if the drug is in a paper
box or in a bottle, to write its purpose on the package: e.g.
for high pressure, for urination, against thrombosis,
against urinary infection etc. The problem of drug treat-
ment in the elderly very often means reducing many
drugs that the patient has been taking previously. It is
also a reason why therapy control is desirable and often
necessary in the elderly (5, 10, 11, 14, 16).
REFERENCES
1. ANDRES R, BIERMAN E L, HAZZARD W R 1985 Principles of
geriatric medicine, McGraw-Hill, New York.
2. SCHRIER R W (ed.) 1990. Geriatric Medicine. WB Saunders, Phi-
ladelphia.
3. DURAKOVI] Z, MI[IGOJ DURAKOVI] M, ^OROVI] N, ^U-
BRILO TUREK M, TUREK S, SCHNAPP MANITA[EVI] A
1996 Hospitalization of older and younger patients in a Department
of Internal medicine – variety of reasons and outcome. Collegium
Antropologicum 20: 213–220
4. HALL W J 1999 Update in geriatrics. Annals of Internal Medicine
131: 842–849
5. HAZZARD W R, BLASS J P, ETTINGER W H Jr, HALTER J B,
OUSLANDER J G (eds) 1999 Principles of geriatric medicine and
gerontology, 4.edition. McGraw-Hill, New York.
6. TRESCH D D, ARONOW W S (eds) 1999 Cardiovascular disease
in the elderly patient. M. Dekker, New York.
7. BEERS M H, BERKOW R 2000 The Merck manual of geriatrics, 3
ed. Whitehouse, NJ.
8. LANDEFELT C S, PALMER R M, JOHNSON M A, JOHNSON
C B, LAONS W L 2004 Current geriatric diagnosis & treatment.
Lange/McGraw-Hill, New York.
9. BOWKER L K, PRICE J D, SMITH S C 2006 Oxford handbook of
geriatric medicine. Oxford Univ. Press.
10. DURAKOVI] Z (ed) 2007 Geriatric – Medicine for the elderly (in
Croatian), CT-poslovne informacije, Zagreb.
11. DURAKOVI] Z (ed) 2011 Geriatric Pharmacotherapy. CT-poslov-
ne informacije, Zagreb.
12. DURAKOVI] Z, MI[IGOJ DURAKOVI] M, ^OROVI] N, PE-
ZEROVI] D@, GA[PAROVI] V, ^UBRILO TUREK M, TUREK
S, \UREK M, NAUMOVSKI MIHALI] M, DE SYO D 1988
Hypothermia and acute renal failure in the elderly. Collegium Antro-
pologicum 22: 5–140
13. DURAKOVI] Z, MI[IGOJ DURAKOVI] M, ^OROVI] N, ^U-
BRILO TUREK M 2000 Urban hypothermia and hyperglycaemia
in the elderly. Collegium Antropologicum 24: 405–409
14. CAYLEY A C D 1987 Hospital geriatric medicine, Arnold, G.B.
15. MI[IGOJ DURAKOVI] M (ed.) 2003 Exercise and health (in
slovenian). The Faculty of the physical culture and the Department
of sport in Slovenia, Ljubljana.
16. SLOAN R W 1986 Practical geriatric therapeutics. Ordell, USA.
520 Period biol, Vol 115, No 4, 2013.
Z. Durakovi} and D. Vitezi} Pharmacodynamics and pharmacokinetics in the elderly
